Dimethyl fumarate accelerates wound healing under diabetic conditions

in Journal of Molecular Endocrinology
Restricted access

Impaired wound healing is a common complication among patients with diabetes mellitus (DM), resulting in high rates of disability and mortality. Recent findings highlighted the critical role of nuclear factor erythroid 2-related factor 2 (NRF2) – a master of cellular antioxidants scavenging excessive DM-induced free radicals – in accelerating diabetic wound healing. Dimethyl fumarate (DMF) is a potent NRF2 activator used for the treatment of multiple sclerosis. However, the effect of DMF on wound healing has not been determined. The present study investigated the effect of DMF on the diabetic and the non-diabetic wound healing in streptozotocin-induced diabetic mice and non-diabetic control mice. DMF activated NRF2 signaling under both conditions. Interestingly, DMF attenuated oxidative damage and inflammation and accelerated wound closure in diabetic mice. However, this effect was not observed in non-diabetic mice. Keratinocytes were treated with normal glucose (NG), high glucose (HG) or hydrogen peroxide (H2O2), in the presence or absence of DMF to assess the role of reactive oxygen species (ROS) – inducible in DM – in mediating DMF-induced protection. Both HG and H2O2 elevated ROS, oxidative damage and inflammation, the effects of which were similarly blunted by DMF. However, in spite of the activation of NRF2, DMF lost this capability under the NG condition. The findings of this study demonstrate that ROS activate the protective effect of DMF on the diabetic wound healing.


      Society for Endocrinology

Related Articles

Article Information


All Time Past Year Past 30 Days
Abstract Views 215 215 57
Full Text Views 344 344 10
PDF Downloads 46 46 5



  • View in gallery

    DMF accelerated wound closure under diabetic, but not non-diabetic conditions. (A) Blood glucose levels 1 week after the last injection of STZ. (B) Representative images of wound closure every other day, for a total period of 10 days after the onset of DM. (C) The percentage of wound closure was calculated. (D) Heat map of wound closure. The data are presented as means ± s.d. (n = 6). *P < 0.05 vs Ctrl; P < 0.05 vs DM. Symbols: red solid square, Ctrl; red hollow square, DM; blue solid circle, Ctrl/DMSO; blue hollow circle, DM/DMSO; orange solid up-triangle, Ctrl/DMF-10; orange hollow up-triangle, DM/DMF-10; green solid down-triangle, Ctrl/DMF-20; green hollow down-triangle, DM/DMF-20; magenta solid left-triangle, Ctrl/DMF-40; magenta hollow left-triangle, DM/DMF-40; navy solid right-triangle, Ctrl/DMF-80; navy hollow right-triangle, DM/DMF-80. Ctrl, control; DM, diabetes mellitus; DMF, dimethyl fumarate; DMF-10, DMF at 10 mg/kg; DMF-20, DMF at 20 mg/kg; DMF-40, DMF at 40 mg/kg; DMF-80, DMF at 80 mg/kg; STZ, streptozotocin.

  • View in gallery

    DMF attenuated cutaneous oxidative damage and inflammation in diabetic mice, but not in non-diabetic mice. (A) Western blotting was used to determine the levels of NRF2 protein. In addition, the expression of (B) Ho1 mRNA and (C) protein was measured using RT-PCR and Western blotting respectively, as a reflection of the function of NRF2. (D) A commercial kit was used to measure the levels of MDA, and RT-PCR was used to determine the mRNA levels of (E) Vcam-1 and (F) Icam-1. The data were normalized to Ctrl and presented as means ± s.d. (n = 6). *P < 0.05 vs Ctrl; P < 0.05 vs DMF-10; P < 0.05 vs DM; §P < 0.05 vs DMF-10. Bars: red solid, Ctrl; red hollow, DM; blue solid, Ctrl/DMSO; blue hollow, DM/DMSO; orange solid, Ctrl/DMF-10; orange hollow, DM/DMF-10; green solid, Ctrl/DMF-20; green hollow, DM/DMF-20; magenta solid, Ctrl/DMF-40; magenta hollow, DM/DMF-40; navy solid, Ctrl/DMF-80; navy hollow, DM/DMF-80. Ho1, heme oxygenase-1; Icam-1, intercellular adhesion molecule-1; MDA, malondialdehyde; NRF2, nuclear factor erythroid 2-related factor 2; Vcam-1, vascular cell adhesion molecule-1. Other abbreviations are the same as those in Fig. 1. A full colour version of this figure is available at https://doi.org/10.1530/JME-18-0102.

  • View in gallery

    Oxidative damage, inflammation, and NRF2 signaling was exhibited prominently in keratinocytes. (A) H&E staining was performed in the Ctrl, DM, and DMF-20 or vehicle-treated DM groups to evaluate morphology of the skin. IHC staining was performed using antibodies against (B) 4-HNE, (C) VCAM-1, (D) NRF2, and (E) HO1 to determine the location of oxidative damage, inflammation, and NRF2 signaling. Positively stained areas of the epidermis, excluding the sebaceous gland were quantified. Symbol: black arrow, positively stained keratinocytes. 4-HNE, 4-hydroxynonenal; IHC, immunohistochemical. Other abbreviations are the same as those in Figs 1 and 2.

  • View in gallery

    NRF2 signaling was activated by H2O2 or HG to a similar extent. Keratinocytes were subjected to NG, H2O2, or HG in the presence or absence of DMF, to measure the levels of (A) NRF2 protein, and the mRNA and protein expression of (B and C) Ho1, and (D and E) Nqo1. The data were normalized to NG and presented as means ± s.d. (n = 3). *P < 0.05 vs NG; P < 0.05 vs NG/DMF; P < 0.05 vs HG. Bars: red solid, NG; blue solid, NG/DMSO; orange solid, NG/DMF; red hollow, NG/H2O2; blue hollow, NG/H2O2/DMSO; orange hollow, NG/H2O2/DMF; green solid, NG/mannitol; red hollow with diagonal stripes, HG; blue hollow with diagonal stripes, HG/DMSO; orange hollow with diagonal stripes, HG/DMF. H2O2, hydrogen peroxide; HG, high glucose; NG, normal glucose; Nqo1, NAD(P)H dehydrogenase quinone 1; ROS, reactive oxygen species. Other abbreviations are the same as those in Figs 1 and 2. A full colour version of this figure is available at https://doi.org/10.1530/JME-18-0102.

  • View in gallery

    DMF alleviated oxidative damage and inflammation in keratinocytes following the generation of sufficient levels of ROS by H2O2 or HG. Keratinocytes were treated with DMF or vehicle, in the presence or absence of H2O2 or HG. The levels of (A) ROS and (B) MDA, along with the mRNA and protein expression of (C and D) Vcam-1 and (E and F) Icam-1 were determined. The data were normalized to NG and was presented as means ± s.d. (n = 3). *P < 0.05 vs NG; P < 0.05 vs NG/H2O2; P < 0.05 vs HG. Bars are the same as those in Fig. 4. Abbreviations are the same as those in Figs 1, 2 and 4. A full colour version of this figure is available at https://doi.org/10.1530/JME-18-0102.

  • View in gallery

    Possible role of ROS in mediating the protection offered by DMF. Under non-diabetic conditions, the wound expresses basal levels of ROS, producing limited levels of free radicals. NRF2 antioxidant signaling is activated in response to basal ROS, scavenging the free radicals and leading to mitigated oxidative damage and inflammation. This mild ROS-induced activation of NRF2 facilitates normal wound healing. On the contrary, under diabetic conditions, ROS are abundantly produced, generating excessive free radicals that exceed the scavenging capacity of NRF2 antioxidant signaling. This effect causes severe oxidative damage and inflammation which impair diabetic wound healing. When treated with DMF, NRF2 signaling is activated under both the diabetic and non-diabetic conditions. Under diabetic conditions, the DMF-elevated antioxidants neutralize ROS-induced excessive free radicals, attenuating oxidative damage and inflammation and accelerating diabetic wound healing. However, under non-diabetic conditions, low levels of free radicals are induced by the lower levels of ROS. This provides insufficient targets for DMF-induced antioxidants. This may explain the non-accelerated wound healing process in the presence of DMF under non-diabetic conditions. Symbols: ↓, activation; , inhibition. Abbreviations are the same as those in Figs 1, 2 and 4. A full colour version of this figure is available at https://doi.org/10.1530/JME-18-0102.


BeckmanJACreagerMALibbyP 2002 Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 25702581. (https://doi.org/10.1001/jama.287.19.2570)

BomprezziR 2015 Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Therapeutic Advances in Neurological Disorders 8 2030. (https://doi.org/10.1177/1756285614564152)

D’AutreauxBToledanoMB 2007 ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nature Reviews Molecular Cell Biology 8 813824. (https://doi.org/10.1038/nrm2256)

DavisFMKimballABoniakowskiAGallagherK 2018 Dysfunctional wound healing in diabetic foot ulcers: new crossroads. Current Diabetes Reports 18 2. (https://doi.org/10.1007/s11892-018-0970-z)

DeliyantiDLeeJYPetratosSMeyerCJWardKWWilkinson-BerkaJLde HaanJB 2016 A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy. Clinical Science 130 13751387. (https://doi.org/10.1042/CS20160068)

DongWJiaYLiuXZhangHLiTHuangWChenXWangFSunWWuH 2017 Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC. Journal of Endocrinology 232 7183. (https://doi.org/10.1530/JOE-16-0322)

DunnillCPattonTBrennanJBarrettJDrydenMCookeJLeaperDGeorgopoulosNT 2017 Reactive oxygen species (ROS) and wound healing: the functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process. International Wound Journal 14 8996. (https://doi.org/10.1111/iwj.12557)

GarstkiewiczMStrittmatterGEGrossiSSandJFeniniGWernerSFrenchLEBeerHD 2017 Opposing effects of Nrf2 and Nrf2-activating compounds on the NLRP3 inflammasome independent of Nrf2-mediated gene expression. European Journal of Immunology 47 806817. (https://doi.org/10.1002/eji.201646665)

GuJChengYWuHKongLWangSXuZZhangZTanYKellerBBZhouHet al. 2016 Metallothionein is downstream of Nrf2 and partially mediates sulforaphane prevention of diabetic cardiomyopathy. Diabetes 66 529542. (https://doi.org/10.2337/db15-1274)

HuSCLanCE 2016 High-glucose environment disturbs the physiologic functions of keratinocytes: focusing on diabetic wound healing. Journal of Dermatological Science 84 121127. (https://doi.org/10.1016/j.jdermsci.2016.07.008)

HulsmansMHolvoetP 2010 The vicious circle between oxidative stress and inflammation in atherosclerosis. Journal of Cellular and Molecular Medicine 14 7078. (https://doi.org/10.1111/j.1582-4934.2009.00978.x)

KampferHSchmidtRGeisslingerGPfeilschifterJFrankS 2005 Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. Diabetes 54 15431551. (https://doi.org/10.2337/diabetes.54.5.1543)

KasparJWNitureSKJaiswalAK 2009 Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radical Biology and Medicine 47 13041309. (https://doi.org/10.1016/j.freeradbiomed.2009.07.035)

KatoMWangMChenZBhattKOhHJLantingLDeshpandeSJiaYLaiJYO'ConnorCLet al. 2016 An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy. Nature Communication 7 12864. (https://doi.org/10.1038/ncomms12864)

LanCCWuCSHuangSMWuIHChenGS 2013 High-glucose environment enhanced oxidative stress and increased interleukin-8 secretion from keratinocytes: new insights into impaired diabetic wound healing. Diabetes 62 25302538. (https://doi.org/10.2337/db12-1714)

LeeYJBaeJHKangSGChoSWChunDINamSMKimCHNamHSLeeSHLeeSHet al. 2017 Pro-oxidant status and Nrf2 levels in psoriasis vulgaris skin tissues and dimethyl fumarate-treated HaCaT cells. Archives of Pharmacal Research 40 11051116. (https://doi.org/10.1007/s12272-017-0955-5)

LinkerRAGoldR 2013 Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Current Neurology and Neuroscience Reports 13 394. (https://doi.org/10.1007/s11910-013-0394-8)

LongMRojo de la VegaMWenQBhararaMJiangTZhangRZhouSWongPKWondrakGTZhengHet al. 2016 An essential role of NRF2 in diabetic wound healing. Diabetes 65 780793. (https://doi.org/10.2337/db15-0564)

LongMCaiLLiWZhangLGuoSZhangRZhengYLiuXWangMZhouXet al. 2017 DPP-4 inhibitors improve diabetic wound healing via direct and indirect promotion of epithelial-mesenchymal transition and reduction of scarring. Diabetes 67 518531. (https://doi.org/10.2337/db17-0934)

NegiGKumarASharmaSS 2011 Nrf2 and NF-kappaB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Current Neurovascular Research 8 294304. (https://doi.org/10.2174/156720211798120972)

PanCZhouSWuJLiuLSongYLiTHaLLiuXWangFTianJet al. 2017 NRF2 plays a critical role in both self and EGCG protection against diabetic testicular damage. Oxidative Medicine and Cellular Longevity 2017 3172692. (https://doi.org/10.1155/2017/3172692)

PiJQuWReeceJMKumagaiYWaalkesMP 2003 Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide. Experimental Cell Research 290 234245. (https://doi.org/10.1016/S0014-4827(03)00341-0)

RoySKhannaSNalluKHuntTKSenCK 2006 Dermal wound healing is subject to redox control. Molecular Therapy 13 211220. (https://doi.org/10.1016/j.ymthe.2005.07.684)

RuizSPergolaPEZagerRAVaziriND 2013 Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney International 83 10291041. (https://doi.org/10.1038/ki.2012.439)

SunWLiuXZhangHSongYLiTLiuXLiuYGuoLWangFYangTet al. 2017 Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1. Free Radical Biology and Medicine 108 840857. (https://doi.org/10.1016/j.freeradbiomed.2017.04.365)

VolpeCMOVillar-DelfinoPHDos AnjosPMFNogueira-MachadoJA 2018 Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death and Disease 9 119. (https://doi.org/10.1038/s41419-017-0135-z)

WangYZhangZGuoWSunWMiaoXWuHCongXWintergerstKAKongXCaiL 2014 Sulforaphane reduction of testicular apoptotic cell death in diabetic mice is associated with the upregulation of Nrf2 expression and function. American Journal of Physiology: Endocrinology and Metabolism 307 E14E23. (https://doi.org/10.1152/ajpcell.00270.2014)

WuHKongLZhouSCuiWXuFLuoMLiXTanYMiaoL 2014a The role of microRNAs in diabetic nephropathy. Journal of Diabetes Research 2014 920134. (https://doi.org/10.1155/2014/920134)

WuHZhouSKongLChenJFengWCaiJMiaoLTanY 2014b Metallothionein deletion exacerbates intermittent hypoxia-induced renal injury in mice. Toxicology Letters 232 340348. (https://doi.org/10.1016/j.toxlet.2014.11.015)

WuHKongLChengYZhangZWangYLuoMTanYChenXMiaoLCaiL 2015 Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2. Free Radical Biology and Medicine 89 431442. (https://doi.org/10.1016/j.freeradbiomed.2015.08.009)

WuHKongLTanYEpsteinPNZengJGuJLiangGKongMChenXMiaoLet al. 2016 C66 ameliorates diabetic nephropathy in mice by both upregulating NRF2 function via increase in miR-200a and inhibiting miR-21. Diabetologia 59 15581568. (https://doi.org/10.1007/s00125-016-3958-8)

WuHWuJZhouSHuangWLiYZhangHWangJJiaY 2018 SRT2104 attenuates diabetes-induced aortic endothelial dysfunction via inhibition of P53. Journal of Endocrinology 237 114. (https://doi.org/10.1530/JOE-17-0672)

XieLGuYWenMZhaoSWangWMaYMengGHanYWangYLiuGet al. 2016 Hydrogen sulfide induces Keap1 S-sulfhydration and suppresses diabetes-accelerated atherosclerosis via Nrf2 activation. Diabetes 65 31713184. (https://doi.org/10.2337/db16-0020)

ZhengHWhitmanSAWuWWondrakGTWongPKFangDZhangDD 2011 Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60 30553066. (https://doi.org/10.2337/db11-0807)


Google Scholar